Personalized approach to the treatment of metastatic kidney cancer
https://doi.org/10.34215/1609-1175-2020-4-63-67
Abstract
Objective: Develop a new organizational form of a personalized approach to assign a target therapy to the patients with metastatic nephrocellular cancer concerning its clinical and economic effectiveness.
Methods: The data by cancer register of the Primorsky region were used. 446 patients are included in the register, it allowed to estimate clinical-economic effectiveness of the target therapy by studying 88 cases.
Results: 5 medicines were used: sunitrib, soraphenib, bevazizumab, everolimus and pazopanib. The control of the progress of the disease and the toxicity covered 44,3% of the patients. The toxicity of the 3–4th levels were registered during the treatment by inhibitors tyrozinkinaz. The target line therapy increased expenditures by 10% and allowed to increase overall survivability to 42 months.
Conclusion: An electronic register of the patients provides monitoring, optimizes expenditures and increases the availability of the target therapy up to 19,7%. Sequential therapy is reasonable and provides the increase of the overall patients’ survivability.
About the Authors
G. N. Alrkseeva
Pacific State Medical University;
Primorsky Regional Cancer Center
Russian Federation
Russian Federation
MD, PhD,
2 Ostryakova Ave., Vladivostok, 690002
L. I. Gurina
Pacific State Medical University;
Primorsky Regional Cancer Center
Russian Federation
Russian Federation
MD, PhD, deputy chief physician,
59 Russkaya St., Vladivostok, 690105
L. F. Pisareva
Tomsk National Research Medical Center of the Russian Academy of Sciences
Russian Federation
Russian Federation
MD, PhD, professor,
5 Kooperativny St., Tomsk, 634009
M. V. Volkov
Tomsk National Research Medical Center of the Russian Academy of Sciences
Russian Federation
Russian Federation
MD, chief physician,
59 Russkaya St., Vladivostok, 690105
N. V. Cherdyntseva
Tomsk National Research Medical Center of the Russian Academy of Sciences
Russian Federation
Russian Federation
MD, PhD, professor, deputy director for research,
5 Kooperativny St., Tomsk, 634009
References
1. Kaprin AD, Starinsky VV, Petrova GV, eds. Malignant neoplasms in Russia in 2015 (morbidity and mortality). Moscow; 2017 (In Russ).
2. Ferlay J. GLOBOCAN 2018 v1. Cancer Incidence and Mortality Worldwide. IARC Cancer Base No. 11. Lyon, France: International Agency for Research on Cancer; 2014. URL: http://globocan.iarc.fr (Accessed: 10 December 2020).
3. Timofeev IV. Renal cell carcinoma. News of the symposium GU ASCO, 2018 (In Russ). URL: https://rosoncoweb.ru/news/oncology/2018/03/05-1 (Accessed: 10 December 2020).
4. Safina SZ, Varlamov SA, Snegovoi AV. Five-year overall survival of patients with metastatic kidney cancer treated with everolimus with progression during treatment with bevacizumab: a prospective multicenter study CRAD001LRU02T. Oncourology. 2017;13(4):40–4 (In Russ).
5. Matveev VB. Nivolumab – a new standard in the treatment of metastatic kidney cancer. Oncourology. 2017;3:18–26 (In Russ).
6. Rini BI, Escudier B, Tomczak P, Karpin A, Szczylik C, Hutson TE, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): A randomised phase 3 trial. Lancet. 2011;378(9807):1931–9.
7. On the problem of refusal of drugs to cancer patients in Russia. Report for 2014. Moscow: MOD “Movement against cancer”; 2015 (In Russ). URL: http://www.rakpobedim.ru/fileadmin/user_upload/pdf/wb2015_1-56 (Accessed: 10 December 2020).
8. Alekseev BYa, Shevchuk IM, Kaprin AD. Possibilities of an individual approach in choosing the 2nd line of targeted therapy for metastatic renal cell carcinoma. Oncourology. 2018;14(2):68–78 (In Russ).
9. Yagudina RI, Serpik VG. Methodological foundations of pharmacoeconomic modeling. Pharmacoeconomics: Theory and Practice. 2016;4(1):7–12 (In Russ).
10. Motzer RJ. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. J Lancet Oncol. 2013;14:552–62.
11. Motzer RJ, Powles T, Atkins MB, Escudier B, McDermott DF, Suarez C, et al. IMmotion151: A randomized phase III study of atezolizumab plus bevacizumab vs sunitinib in untreated metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2018;36(6S):578.
12. Atkins MB, Plimack ER, Puzanov I, Fishman MN, McDermott DF, Cho DC, et al. Safety and efficacy of axitinib (axi) in combination with pembrolizumab (pembro) in patients (pts) with advanced renal cell cancer (aRCC). J Clin Oncol. 2018;36(6S):579.
13. Alekseev BYa, Kalpinskiy AS, Mukhomedyarova AA, Nyushko KM, Kaprin AD. Targeted therapy of patients with metastatic kidney cancer of a poor prognosis. Oncourology. 2017;2:49–55 (In Russ).
Review
For citations:
Alrkseeva G.N., Gurina L.I., Pisareva L.F., Volkov M.V., Cherdyntseva N.V. Personalized approach to the treatment of metastatic kidney cancer. Pacific Medical Journal. 2020;(4):63-67. (In Russ.) https://doi.org/10.34215/1609-1175-2020-4-63-67
Views:
617
Email this article 